Form 4: Acrivon Therapeutics Officer's Routine Stock Transaction

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, reported a routine disposition of shares for tax withholding purposes.

Summary

• Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on August 14, 2025.
• The transaction involved the disposition of 184 shares of Common Stock.
• These shares were withheld by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• The shares were disposed of at a price of $1.39 per share.
• Following this transaction, Mary Miller beneficially owns 35,581 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction for tax withholding, which is neutral in sentiment and does not indicate positive or negative company performance or insider sentiment.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction for tax purposes and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a small, routine, non-discretionary transaction for tax purposes, not a sale for liquidity or a change in investment thesis.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, SEC Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Restricted Stock Units, Corporate Officer